Peptide-based therapies offer the potential to transform how we treat a range of conditions - but have yet to be adopted for widespread clinical use. A new review uncovers the barriers to adoption and identifies ways to overcome these limitations.
Researchers have pioneered a microbially driven process that utilises low-value waste products, such as magnesium mine waste and sulfur from desulfurisation plants, to leach the wastes and generate a stream of solubilised magnesium.
